Down 17% with a P/E of 9.4! Is this dividend star the best share to buy after recent good news?

Harvey Jones reckons this former FTSE 100 darling could be the best share for him to buy today given its low price and rising yield. Yet recent performance has been poor.

| More on:

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Could the very best share to buy today be one I already hold? I certainly hope so, but there’s a mystery at the heart of this one.

The company in question is pharmaceutical giant GSK (LSE: GSK). In its former incarnation as GlaxoSmithKline, this was one of the most popular and admired FTSE 100 stocks of all.

It was a true Dividend Aristocrat, regularly yielding around 5.5% a year, while holding out the prospect of long-term share price growth too.

No stock smashes it forever though. Glaxo hit blockages in its drugs pipeline as it struggled to replace blockbuster treatments that had gone off patent. CEO Emma Walmsley responded by freezing dividend payments at 80p a share for what seemed like forever, and diverting the savings into R&D.

The shares are a shocker

While that was a shame for income seekers, I understood her thinking and assumed it would generate superior returns over time.

Many thought peeling off consumer healthcare arm Haleon would help, too. It certainly helped Haleon, whose shares have climbed nicely, but has it worked for GSK? Not so much. Its shares are down 0.99% over one year. But over five years, they’re down 17.25%, which is rubbish, frankly.

The GSK share price has fallen 11.3% over the last six months but I wasn’t too concerned, because there was a legal shadow hanging over the company.

GSK had pulled blockbuster heartburn drug Zantac from sale in the US in 2019, following claims that it contained “unacceptable levels” of probable cancer-causing ingredients. GSK called this “inconsistent with the science” and it went to court.

I still think it’s too cheap to resist

The shares crashed 9% on 3 June after a Delaware judge gave the green light to 70,000 Zantac lawsuits. Then Morgan Stanley terrified investors by claiming GSK could take a staggering $30bn hit.

Having bought GSK shares, I was terrified too. But there was a little I could do apart from hang on and hope Morgan Stanley was wrong. So imagine my joy when GSK agreed a $2.2bn settlement covering more than 90% of all legal claims. On 9 October, its shares jumped more than 6% on the news.

And then they fell again. What gives? We’ve all seen how FTSE 100 rival AstraZeneca has transformed itself into the UK’s biggest company. Surely Glaxo can get a piece of that? Not yet, is the disappointing answer. 

GSK has reported a string of positive trial results in the last couple of weeks without moving the dial. But with the stock trading at 9.38 times earnings, well below the FTSE 100 average of 15.4 times, I still think there’s plenty of value here.

Analysts remain optimistic, with the 18 brokers offering one-year price forecasts setting a median share price target of 1,837.5p. If they’re right, that’s up 27.85% from today.

GSK’s yield has crept up to 4%. That’s still below the glory days, but okay. I wouldn’t say GSK is the very best FTSE 100 share to buy today, but it still looks good value to me. I’ll top up my stake the moment I have the cash.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Harvey Jones has positions in GSK. The Motley Fool UK has recommended AstraZeneca Plc, GSK, and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

5 steps to start buying shares with under £500

Learn how this writer would start buying shares with a few hundred pounds in a handful of steps, if he…

Read more »

Young happy white woman loading groceries into the back of her car
Investing Articles

The FTSE 100 offers some great bargains. Is this one?

Our writer digs into one FTSE 100 share that has had a rough 2024 to date, ahead of its interim…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£9,000 of savings? Here’s my 3-step approach to aim for £1,794 in passive income

Christopher Ruane walks through the practical steps he would take to try and turn £9,000 into a sizeable passive income…

Read more »

Group of young friends toasting each other with beers in a pub
Investing Articles

I’d buy 29,412 shares of this UK dividend stock for £150 a month in passive income

Insiders have been buying this dividend stock, which offers an 8.5% yield. Roland Head explains why he’d choose the shares…

Read more »

Red briefcase with the words Budget HM Treasury embossed in gold
Investing Articles

Could the new UK budget spell growth for these 6 FTSE stocks? I think so!

Mark David Hartley considers six UK stocks that could enjoy growth off the back of new measures announced in the…

Read more »

Investing Articles

With a 6.6% yield, is now the right time to add this income stock to my ISA?

Our writer’s looking to boost his Stocks and Shares ISA. With this in mind, he’s debating whether to buy a…

Read more »

Dividend Shares

This blue-chip FTSE stock just fell 12.5% in a day. Is it time to consider buying?

Smith & Nephew is a well-known, blue-chip FTSE stock with a decent dividend yield. And its share price just dropped…

Read more »

Investing Articles

At 72p, the Vodafone share price looks to be at least 33% undervalued to me

Our writer looks at a number of valuation measures to determine whether the Vodafone share price reflects the fair value…

Read more »